BioAge Fell 64%. Its Drug Had Not Failed.
The market sold BioAge after another company's inflammation drug failed. Get the free investor briefing on what changed, what did not, and which evidence matters next.
This website uses cookies
Read our Privacy policy and Terms of use for more information.
The market sold BioAge after another company's inflammation drug failed. Get the free investor briefing on what changed, what did not, and which evidence matters next.